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Available online 8 November 2012Nontyphoidal Salmonellae (NTS) are a common cause of bacteraemia in children and HIV-
infected adults in Sub-Saharan Africa. We have previously shown that antibodies play a key
role in both bactericidal and cellular mechanisms of immunity to NTS, but found that high
concentrations of antibody to Salmonella Typhimurium O antigen (OAg) in the serum of some
HIV-infected African adults is associated with impaired killing of NTS. To further investigate
the function of antibodies to the OAg of NTS, we developed a method to purify these antibodies
from human serum by affinity chromatography. Purified Salmonella Typhimurium OAg was
activated with adipic acid dihydrazide (ADH) via two different chemistries before linking to
N-hydroxysuccinamide-Sepharose resin: one ADH molecule was introduced per OAg chain on
its terminal 3-deoxy-D-manno-octulosonic acid sugar (OAg–ADH), or multiple ADH molecules
were attached along the OAg chain after oxidation with sodium periodate (OAgoxADH). Both
resulting columns worked well when tested with commercial polyclonal anti-O:4,5 antibodies
from rabbit serum. Over 90% of the applied antibodies bound to the resin and 89% of these
antibodies were then eluted as detected by ELISA. OAg–ADH was preferred as the method for
OAg derivatisation as it does not modify the saccharide chain and can be applied to OAg from
different bacteria. Both columns were able to bind OAg-specific antibodies in human serum,
but antibody recovery was initially low. Different elution buffers were tested and different
amounts of OAg–ADH were linked to the resin to improve the yield. Optimal recovery (51%)
was obtained by loading 1 mg of activated OAg per ml of resin and eluting with 0.1 M glycine,
0.1 M NaCl pH 2.4. The column matrix could be regenerated following elution with no
detectable loss in performance for over ten uses. This method offers the potential to purify
antibodies to Salmonella OAg from polyclonal serum following vaccination or natural exposure
to Salmonella and so investigate the functionality and diversity of the antibody response to OAg.
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Y-NC-ND license. 1. Introduction
Nontyphoidal Salmonellae (NTS), including Salmonella
enterica serovars Typhimurium (S. Typhimurium) and
Enteritidis (S. Enteritidis) are a common cause of bacteraemia
in children and HIV-infected adults in Sub-Saharan Africa
(Morpeth et al., 2009; Reddy et al., 2010; Gordon et al., 2008).
The case fatality rate for bacteraemia caused by NTS is 20–
25% for children (Graham et al., 2000; Brent et al., 2006) and
increases to 50% for children with NTS meningitis (Molyneux
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HIV-infected adults with NTS bacteraemia (Gordon et al.,
2002).
We have previously shown that antibodies play a key role in
both bactericidal (MacLennan et al., 2008) and cellular (Gondwe
et al., 2010) mechanisms of immunity to NTS. The highest
incidence of NTS bacteraemia occurs in children aged between
3 and 24 months, when antibody levels are low (MacLennan et
al., 2008). A decrease in cases is found in African children aged
over 2 years, corresponding to the acquisition of antibody
which is able to initiate both complement-dependent killing of
Salmonella (MacLennan et al., 2008) as well as effective
opsonisation and subsequent uptake by blood phagocytes
(Gondwe et al., 2010), thus emphasising the importance of
antibody. The targets of bactericidal and opsonic antibodies on
invasive African NTS have not been fully defined. There is good
support for the protective efficacy in mice of antibody against
Salmonella outer membrane proteins, in particular OmpD
(Gil-Cruz et al., 2009). There is also evidence that antibodies
against the O antigen (OAg) of the lipopolysaccharide (LPS)
molecule of Salmonella are protective (Jorbeck et al., 1981;
Svenson and Lindberg, 1981). Passive transfer of monoclonal
antibodies raised to smooth LPS, but not rough LPS that lacks the
OAg chain, conferred significant protection in mice (Singh et al.,
1996) and immunizationwith S. Typhimurium and S. Enteritidis
OAg conjugates conferred protection to challenge (Simon et al.,
2011; Watson et al., 1992). However, we have also found that
HIV-infected African adults have impaired humoral immunity
to NTS associated with dysregulated production of antibodies to
the OAg of S. Typhimurium (MacLennan et al., 2010) and this
warrants further investigation. Despite its probable importance,
little is known about the natural immune response to LPS. The
capacity to purify LPS-specific antibodies would, for example, be
useful in analysing V region usage. Purification of Salmonella
OAg-antibodies from polyclonal sera would allow further char-
acterisation of both the functionality and specificity of these
antibodies. This would facilitate the ongoing investigation of
their potential protective and blocking effects in individuals
immunised with OAg-based vaccines and in HIV-infected
African adults.
Monoclonal and polyclonal antibodies are conventionally
purified by affinity chromatography (Cuatrecasas, 1970; Jack,
1994; Huse et al., 2002), using the highly-specific nature of
the interaction between antigen and antibody. The antigen is
covalently attached to a solid support under conditions that
retain antibody-binding capacity. Subsequently, when serum is
passed over the antigen-bound column, only those molecules
with specific affinity for the antigen are bound. After washing,
the bound antibodies are eluted, thereby purifying them from
the original sample. Although thismethod for recovering active
antibodies is potentially selective, rapid and simple, allowing
antibody purification in a single chromatographic step, the
recovery is typically low (Casey et al., 1995; Cuatrecasas and
Anfinsen, 1971). Optimised conditions need to be determined
to permit efficient purification of the desired antibodies with-
out altering their native structure (Narhi et al., 1997a).
Salmonella LPS consists of lipid A linked to the 3-deoxy-
D-manno-octulosonic acid (KDO) terminus of the conserved
core region, which in turn is linked to the serovar-specific OAg
chain. The OAg chain is the immunodominant portion of the
molecule and extends as a repeating polymer from the end ofthe core region (Whitfield et al., 2003). In S. Typhimurium, the
OAg repeat (O:4,5) consists of a trisaccharide backbone, with a
branch of abequose, usually O-acetylated on C-2, which confers
serogroup specificity (factor 4,5) (Fig. 1A) (Hellerqvicst et al.,
1969).
LPS detoxification is usually performed by acetic acid
hydrolysis or by hydrazinolysis (Konadu et al., 1996), with the
former commonly preferred as it retains the O-acetyl groups
along the OAg chain. Acid hydrolysis cleaves the labile linkage
between Lipid A and KDO leaving the OAg chain attached to
the core region (Fig. 1A).
Many approaches have been used to bind LPS or detoxified
OAg from various bacteria to resins for use in affinity puri-
fication and, despite the high toxicity, CNBr-activated resin
has been the most commonly employed (Stiller and Nielsen,
1983; Rodahl and Maeland, 1984). Girard and Goichot
attached LPS to an aminohexyl-Sepharose resin by activation
with benzoquinone (Girard and Goichot, 1981), while Fox
andHechemy tested epoxy-activated resin for the attachment
of Escherichia coli LPS (Fox and Hechemy, 1978). The bound
LPS showed low antibody binding capacity, which may be
due to limited availability of antibody-binding sites on LPS
resulting from steric hindrance and/or partial hydrolysis as
a result of the alkaline pH used for the LPS coupling to the
resin. Altman and Bundle showed that an epoxy-activated
Sepharose-gel worked well with underivatised Salmonella
Essen OAg, but OAg from other bacteria did not couple to this
activated support (Altman and Bundle, 1994). They proposed
the use of epoxy- or succinimide ester-activated Sepharose
after OAg derivatisation with a 1,3-diaminopropane spacer.
For anti-NTS OAg antibody purification, affinity chroma-
tography columns are not commercially available. We devel-
oped and compared two alternative strategies for inserting
hydrazide groups into the OAg of S. Typhimurium prior to
linking to commercially available N-hydroxysuccinamide
(NHS)-Sepharose resin. The resulting affinity columns were
tested for their ability to isolate antibodies from human serum
against the OAg of LPS from S. Typhimurium D23580, a char-
acteristic invasive African isolate of NTS (Kingsley et al., 2009).
2. Materials and methods
2.1. Chemicals
Unless otherwise stated, chemicals and reagents were
from Sigma.
2.2. Commercial anti-O:4,5 antibody
Polyclonal monovalent anti-O:4,5 Salmonella Typhimurium
antibodies raised in rabbits (Bio-Rad 59021C) were used as a
source of purified antibodies. This antiserum was obtained by
immunizing rabbits with selected strains of Salmonella. Mono-
valent sera were adsorbed in order to increase their specificity.
2.3. S. Typhimurium bacterial isolate
S. Typhimurium D23580, a well-characterized invasive
clinical isolate of nontyphoidal Salmonella from Malawi
(MacLennan et al., 2008; Kingsley et al., 2009) was used
throughout the study. This strain is representative of 90% of
AB
C
Fig. 1. Structure of S. TyphimuriumOAg chain and core region following acid hydrolysis of LPS and reaction schemes for production of activated OAg. The structure of the S.
Typhimurium OAg chain linked to the core region after acetic acid hydrolysis. Hydrolysis removes Lipid A leaving the OAg chain attached to the core. Core region structure
taken from Jansson, et al [P.E. Jansson, A.A. Lindberg, B. Lindberg, R. Wollin, Structural studies on the hexose region of the core in lipopolysaccharides from
Enterobacteriaceae, Eur. J. Biochem. 115 (1981) 571–7] (A). Reaction scheme for OAg–ADH: the ketone group of the terminus KDO is linked to ADH by reductive amination
(B). Reaction scheme for OAgoxADH: diol groups are oxidised to aldehyde groups by NaIO4. These aldehyde groups can then react with ADH by reductive amination (C).
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bioreactor (EZ-Control, Applikon) to an OD of 35 as previously
described (Rondini et al., 2011).
2.4. OAg puriﬁcation
The OAg was purified according to a new method devel-
oped at Novartis Vaccines Institute for Global Health. Briefly,acid hydrolysis (2% acetic acid at 100 °C for 3 h) was
performed directly on the bacterial fermentation culture and
OAg was recovered from the supernatant by centrifugation.
Lower molecular weight impurities were removed by tan-
gential flow filtration (TFF), using a Hydrosart 30 kDa mem-
brane. Protein and nucleic acid impuritieswere co-precipitated
in citrate buffer 20 mM at pH 3. Proteins were further re-
moved by ion exchange chromatography and nucleic acids
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CaCl2, to give final concentrations of 18 mM, 24% and 200 mM
respectively. OAg was recovered in water by a second TFF
30 kDa step.
2.5. Activation of OAg with ADH
2.5.1. Selective activation of KDO
OAg was solubilized in 100 mM sodium acetate (AcONa)
buffer pH 4.5 at a concentration of 40 mg/ml. Adipic acid
dihydrazide (ADH), and then sodium cyanoborohydride
(NaBH3CN) were added as solids, both at a ratio of 1.2:1 by
weight with respect to the OAg. The solution was mixed at
30 °C for 1 h before purifying by desalting against water on a
G-25 column (HiTrap™ desalting column 5 ml or HiPrep™
26/10 desalting column 53 ml, pre-packed with Sephadex™
G-25 Superfine; GE Healthcare). The derivatised OAg was
indicated as OAg–ADH (Fig. 1B).
2.5.2. Random activation along the OAg chain after oxidation
with sodium metaperiodate (NaIO4)
OAg was solubilized in 0.1 M AcONa buffer pH 5 and
100 mM freshly prepared NaIO4 added to give 6.25 mM
NaIO4 in the reaction mixture with OAg at a concentration of
10 mg/ml. The mixture was incubated for 2 h at room tem-
perature in the dark, and then purified by desalting against
water on a G-25 column. The oxidised OAg was dried in a
SpeedVac vacuum centrifuge (Thermo SPD 131DDA) (room
temperature, overnight, 500 mtorr), and then activated with
ADH following the same procedure described above. The final
product was indicated as OAgoxADH (Fig. 1C).
2.6. Analytical methods
The phenol sulphuric assay was used for total sugar content
quantification (DuBois et al., 1956). OAg impurities were
assessed bymicro BCA (Bicinchoninic Acid) for protein content
(using bovine serum albumin as a reference and following the
manufacturer's instructions [Thermo Scientific]) and by UV
spectroscopy for nucleic acids (at a wavelength of 260 nm
assuming that a nucleic acid concentration of 50 μg/ml pro-
duces an OD260 of 1). The chromogenic kinetic LAL (Limulus
Amoebocyte Lysate) Assay was used to measure endotoxin
level (Charles River Endosafe-PTS instrument).
2.6.1. Size exclusion high pressure liquid chromatography
(HPLC-SEC)
HPLC-SEC analysis was used to estimate the molecular size
distribution of OAg populations. Samples were run on a TSK gel
G3000 PWXL column (30 cm×7.8 mm; particle size 7 μm; cod.
808021) with TSK gel PWXL guard column (4.0 cm×6.0 mm;
particle size 12 μm; cod.808033) (TosohBioscience). The
mobile phase was 0.1 M NaCl, 0.1 M NaH2PO4, and 5%
CH3CN, pH 7.2 at a flow rate of 0.5 ml/min (isocratic method
for 30 min). Void and bed volume calibration was performed
with λ-DNA (λ-DNA molecular weight marker III 0.12–
21.2 Kbp, Roche) and sodium azide (NaN3, Merck), respec-
tively. OAg peaks were detected by differential refractive
index (dRI). For kd determination, the following equation
was used: kd=(Te−T0)/(Tt−T0) where: Te = elution timeof the analyte, T0 = elution time of the biggest fragment of
λ-DNA and Tt = elution time of NaN3.
2.6.2. High-performance anion-exchange chromatography with
pulsed amperometric detection (HPAEC-PAD)
Rhamnose (Rha), galactose (Gal), glucose (Glc) and man-
nose (Man), each occurring once in the OAg chain repeating
unit, and N-acetyl glucosamine (GlcNAc), sugars present in
the core region only, were estimated by HPAEC-PAD after
acid hydrolysis of the OAg to release the monosaccharides.
Commercial monomer sugars were used for building the
calibration curves. For Rha, Gal, Glc and Man quantification,
OAg samples, diluted to have each sugarmonomer in the range
0.5–10 μg/ml, were hydrolyzed at 100 °C for 4 h in 2 M TFA.
These hydrolysis conditions were optimal for release of all
monomerswithout their degradation. For GlcNAc quantification,
OAg samples, diluted to a GlcNAc concentration of 0.5–10 μg/ml,
were hydrolyzed at 100 °C for 6 h in 1 M TFA. After the
hydrolysis, samples were chilled at 2–8 °C for about 30 min,
dried by vacuum centrifuge overnight, reconstituted in water
and filtered using 0.45 μm Acrodisc (Pall) filters prior to
chromatographic analysis.
HPAEC-PAD was performed with a Dionex ICS3000
equippedwith a CarboPac PA10 column (4×250 mm) coupled
with PA10 guard column (4×50 mm). Separation of the sugars
was performed with a flow rate of 1 ml/min eluting in a
gradient from 10 mM NaOH to 18 mM NaOH over 20 min.
After washing for 20 min with 100 mM AcONa in 28 mM
NaOH, the column was re-equilibrated with 10 mM NaOH for
20 min. The effluent was monitored using an electrochemical
detector in the pulse amperometric mode with a gold working
electrode and an Ag/AgCl reference electrode. The Dionex
standard quadruple-potentialwaveform for carbohydrateswas
used. The resulting chromatographic data were processed
using Chromeleon software 6.8. Calibration curves were built
for each sugar monomer (0.5–10 μg/ml). The standards were
hydrolysed and analysed in the same way as the samples.
For GlcNAc, glucosamine (GlcN) was the species detected by
HPAEC-PAD after hydrolysis.
2.6.3. Proton nuclear magnetic resonance (1H NMR)
spectroscopy
1H NMR analysis was performed to estimate the
O-acetylation level. It was also used to confirm the identity
of the OAg samples (typical signals of the OAg chain can be
detected, confirming the presence of the characteristic
sugars) and in particular for calculating the molar ratio of
Rha to abequose (Abe) by comparing the integrals of the two
peaks corresponding to Rha-H6 and Abe-H6.
The dried OAg sample was subsequently solubilized in
deuterium oxide (D2O) and transferred to a 5 mmNMR tube. A
first spectrum was collected in D2O and a second one after
de-O-acetylation achieved by adding sodium deuteroxide
(NaOD) to a final 200 mM concentration and heat treatment
(37 °C for 2 h for complete de-O-acetylation). The first 1HNMR
spectrum was recorded to ensure the absence of impurities at
the same chemical shift of the acetate anion released after
de-O-acetylation of the sample that would interfere with the
quantification of the O-acetyl content. O-acetylation level was
quantified by comparing acetate (released after treatment
with NaOD) and Rha-H6 peaks, and expressed as molar % of
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Rha present only in the OAg chain at one sugar per repeating
unit).
NMR experiments were recorded at 25 °C on Varian
VNMRS-500 spectrometer, equipped with a Pentaprobe.
Acquisition time of 5 s, relaxation delay of 15 s and number
of scans of 64 was set for the acquisition of the spectra. For
data acquisition and processing VNMRJ ver. 2.2 rev. C and
Mestrenova 6.1 (Mestrelab Research) were used respectively.
1-D proton NMR spectra were collected using a standard
one-pulse experiment. Chemical shifts were referenced to
hydrogen deuterium oxide (HDO) at 4.79 ppm (1 H).2.6.4. KDO quantiﬁcation by semicarbazide/HPLC-SEC method
OAg samples were analysed by HPLC-SEC after deriva-
tisation with semicarbazide to quantify α-ketoacid present
at the terminus KDO. This reaction was performed as a slight
modification of the semicarbazide assay for α-ketoacids de-
termination (Macgee and Doudoroff, 1954). OAg samples and
KDO standards (100 μl of total volume in water), with a C_O
concentration between 15.7 nmol/ml and 156.7 nmol/ml,
were added to 100 μl of semicarbazide solution (100 mg
semicarbazide hydrochloride+90.5 mg of sodium acetate
anhydrous in 10 ml of water). Sample blanks were prepared
by adding 100 μl of sodium acetate (90.5 mg of sodium
acetate anhydrous in 10 ml of water) to 100 μl of the OAg
samples at the same concentration used for the analysis. All
samples and standards were heated at 50 °C for 50 min and
then analysed by HPLC-SEC (80 μl injected), on a TSK gel
G3000 PWXL column with guard column in 0.1 M NaCl,
0.1 M NaH2PO4, 5% CH3CN, pH 7.2 mobile phase at the flow
rate of 0.5 ml/min (isocratic method for 30 min). Detection
was done at 252 nm. The area under the peak corresponding
to the OAg after derivatisation with semicarbazide was
corrected with the area of the corresponding blank and the
amount of KDO calculated with the calibration curve built
with the areas of KDO standards at 252 nm.2.6.5. NH2 quantiﬁcation and calculation of OAg derivatisation
with the linker ADH
The trinitrobenzene sulfonic acid (TNBS) colorimetric
method (Palmer and Peters, 1969; Satake et al., 1960) was
used for total NH2 group quantification. 6-aminohexanoic
acid was used as the standard for NH2 quantification on
underivatised OAg samples, while ADH was used as the
standard for NH2 quantification after OAg derivatisation with
ADH. The amount of hydrazide groups introduced linking
ADHwas calculated by subtracting the number of NH2 groups
already present on the un-derivatised OAg sample and the
number of free NH2 groups, detected as free ADH by reverse
phase high performance liquid chromatography (RP-HPLC)
(Micoli et al., 2012) from the total NH2 groups by TNBS.
Selective activation on the terminal KDO was calculated as
the percentage of moles of linked ADH per moles of GlcNAc
(present as a unique sugar in the core region, Fig. 1), indicating
the percentage of activated OAg chains. Random activation
with ADH after oxidation was expressed as the percentage of
moles of ADH per moles of Rha (present as one sugar per OAg
repeating unit; Fig. 1).2.7. Derivatised OAg coupling to NHS-Sepharose
Immobilization of the derivatised OAg samples, both OAg–
ADH and OAgoxADH, on NHS-Sepharose was performed
according to the manufacturer's instructions (GE Healthcare).
Briefly, OAg–ADH or OAgoxADH was dissolved in coupling
buffer (5–10 mg/ml; 0.5 M NaCl, 0.2 M NaHCO3, pH 8.3). A
HiTrap™ NHS-activated HP 1 ml column was washed with
1 mM HCl (6 column volumes) and dissolved activated OAg
was added to the column and incubated overnight at 4 °C. The
column was then washed with 0.5 M ethanolamine, 0.5 M
NaCl pH 8.3 (6 column volumes) to block unreacted sites
followed by 0.1 M AcONa, 0.5 M NaCl pH 4 (6 column
volumes). Washing with 0.5 M ethanolamine, 0.5 M NaCl
pH 8.3was repeated (6 column volumes) and the columnwas
left at 4 °C for 4 h. 0.1 M AcONa, 0.5 M NaCl pH 4, 0.5 M
ethanolamine, 0.5 M NaCl pH 8.3 and again 0.1 M AcONa,
0.5 M NaCl pH 4 were passed through the column (6 column
volumes for each buffer). The column was stored in 0.05 M
Na2HPO4, 0.1% NaN3 pH 7.0 at 4 °C. A syringe was used for all
wash steps. Flow through and wash solutions were analysed
by phenol sulphuric assay to calculate the amount of sugar
linked to the resin.
2.8. Sera preparation
Blood containing anti-Salmonella antibodieswas venesected
from a healthy adult and left to clot at 22 °C for 4 h before
separating by centrifugation at 4 °C and freezing in aliquots at
−80 °C. Ethical approval for the use of human serum in this
study was granted by the Life and Health Sciences Ethical
Review Committee of the University of Birmingham. Informed
written consent was obtained prior to venesection.
2.9. Ammonium sulphate precipitation of serum proteins
Ammonium sulphate was added as a solid to 1 ml of
human serum to give a final concentration of 0.5 g/ml and the
mixturewas placed on ice for 5 min. The serumwas centrifuged
at 4 °C, 3300×g for 5 min and the supernatant discarded. The
precipitate was washed twice with 1 ml 0.5 g/ml ammonium
sulphate. The pellet was solubilized in 0.3 ml PBS and dialysed
overnight against PBS at 4 °C.
2.10. Anti-Salmonella Typhimurium OAg antibodies puriﬁcation
by afﬁnity chromatography
NHS HiTrap columns with activated OAg were equilibrated
with PBS (6 column volumes) before applying the serum
protein solution to the columnand incubating overnight at 4 °C.
Columns were then washed with PBS (6 column volumes),
followed by 50 mM NaH2PO4, 500 mM NaCl pH 7.2 (6 column
volumes). Bound antibodies were eluted in 5 column volumes
of elution buffer, collecting fractions of 0.5 ml each. 0.1 M
glycine, 0.1 MNaCl at pH 2.4, 2.6, 2.8 and 3.0; 20% ethanol; 4 M
MgCl2 in 10 mM Tris base pH 7; 8 M urea; and 100 mM Tris
base pH 9were tested as elution buffers. Following elutionwith
glycine buffers using a pH 2.4–3.0, the pH was adjusted to 7.0
with 2 M Tris pH 9. Individual eluate fractions were analysed
for protein content by measuring absorption at 280 nm. After
elution, all eluates were dialysed overnight against PBS at 4 °C.
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on columns was investigated by applying 1% SDS to columns
andanalysing SDS-eluates by SDS-PAGE. Columnswerewashed
with PBS and stored in 0.05 M Na2HPO4, 0.1% NaN3 pH 7.0 at
4 °C.
2.11. ELISA for anti-Salmonella Typhimurium OAg antibody
96-well flat bottom plates (NUNC Maxisorp) were incu-
bated with 100 μl per well of 5 μg/ml TLR-grade smooth LPS
from S. Typhimurium (Alexis Biochemicals) or 15 μg/ml
S. Typhimurium OAg, overnight at 4 °C. After coating, plates
were washed with PBS 0.05% Tween and incubated with
200 μl blocking buffer (PBS 1% BSA) per well for 1 h at 37 °C.
Plates were washed again with PBS 0.05% Tween and
incubated for 1 h at 37 °C with 100 μl serial dilutions of
antibody solution diluted with PBS 1% BSA 0.05% Tween.
Following further washes, 100 μl of goat-antihuman alkaline-
phosphatase-labelled IgG (Southern Biotech) was added to
each well and plates were incubated for 1 h at 37 °C. Plates
were washed to remove unbound antibody and bound anti-
body detected using 100 μl p-Nitrophenyl phosphate solu-
tion. The reciprocal of the concentration of antibody giving an
OD of 1 at λ 405 nmwas calculated. This value was plotted as
the anti-Salmonella Typhimurium IgG concentration. The
recovery of purified antibody was determined by multiplying
the anti-Salmonella Typhimurium IgG ELISA concentration of
each eluate by the appropriate dilution factor and dividing
their sum by the anti-Salmonella IgG concentration for the
human serum protein solution bound to the column. This
value was expressed as the percentage recovery of purified
anti-OAg antibody.
3. Results
3.1. OAg puriﬁcation, activation with ADH and coupling to
NHS-Sepharose
OAg from S. Typhimurium D23580 was purified by acetic
acid hydrolysis of bacterial fermentation broth with the direct
release of OAg into the supernatant. This avoids the need for hot
phenol LPS extraction followed by LPS detoxification (Simon et
al., 2011; Konadu et al., 1996;Watson et al., 1992). Purified OAg
contained 0.4% protein, 0.15% nucleic acid (w/wwith respect to
total sugar content), with an endotoxin levelb0.01 UI/μg. The
O-acetyl content was 142% (expressed as molar ratio of OAc
groups to Rha)which is likely to represent O-acetylation of Rha,
as well as Abe, as previously described following lysogenisation
of S. Typhimurium with bacteriophages A3 and A4 (Wollin
et al., 1987). This is an unusual and interesting finding which
may distinguish African invasive S. Typhimurium isolates from
those found elsewhere and could impact on the polyclonal
antibody response to S. TyphimuriumOAg in Africa. Analysis by
HPLC-SEC (dRI) revealed the presence of twomain populations
with different average MW, with kd values of 0.18 and 0.30
respectively. Analysis of the two separated populations by
HPAEC-PAD indicated an average number of repeatingunits per
OAg chain of 71 and 25 respectively, calculated from the molar
ratio of Rha to GlcNAc (basic structure of OAg and core region of
S. Typhimurium LPS shown in Fig. 1A). GlcNAc quantification
was in good agreement with KDO quantification, confirmingthe presence of one KDO per OAg chain. The molar ratios of
Man, Gal, Glc and Abe to Rha were respectively 1.05, 1.08, 0.41
and 1.04. OAg contained 24.1% NH2 groups pre-derivatisation
with ADH (expressed asmolar ratio % of NH2 groups toGlcNAc),
probably as pyrophosphoethanolamine residues in the core
region (Fig. 1A).
Two different chemistries were used for inserting reactive
hydrazide groups into the OAg prior to linking to commer-
cially available NHS-Sepharose. For one method, the KDO
sugar at the end of the core region was linked through
reductive amination to one ADH molecule, thus producing
OAg–ADH (Fig. 1B).With the secondmethod, OAg underwent
an oxidative step prior to activation with ADH (Fig. 1C). Diol
moieties are susceptible to oxidation with NaIO4, producing
aldehyde groups along the length of the OAg chain that can
then react with ADH by reductive amination. In contrast to
the first method, the OAg chain was modified with multiple
ADH linkers introduced along the saccharide chain. All of the
OAg–ADH preparationswere characterized by a sugar recovery
greater than 80%, with more than 80% of OAg chains activated
and b2% (in moles) of free to linked hydrazide groups. We
confirmed the absence of dimer and aggregate formation with
the reaction condition used by analysing the OAg–ADH using
HPLC-SEC. This showed the presence of one peakwith the same
kd value as the underivatised OAg. The OAgoxADH preparation
was characterized by a total sugar recovery of 73%, with 20%
activation (molar % linked ADH to Rha) and b2% free to linked
hydrazide groups. In theory, the presence of more than one
ADH linker per OAg chain in OAgoxADH could favour the OAg
binding to the NHS-Sepharose. However the binding capacity
was found to be 3.7 mg of OAgoxADH and 4.3 mg of OAg–ADH
per ml of resin.
3.2. Evaluating the antigenic integrity of derivatised OAg
The prepared affinity columns were tested with a
commercially-available preparation of purified polyclonal
rabbit anti-Salmonella Typhimurium O:4,5 antibodies to
determine if the hydrolysis and activation of OAg with ADH
had impaired the antigenic structure of the OAg. 3.7 and
4.3 mg of OAgoxADH and OAg–ADH respectively were linked
to NHS-Sepharose columns and 300 μl of O:4,5 antibodies
(with an antibody concentration corresponding to 1666 ELISA
units) were applied to each column. 92% of the antibodies
bound to the OAg–ADH column (Fig. 2A) and 96% bound to
the OAgoxADH column (Fig. 2B) with the remaining applied
antibodies detected in the flow through and subsequent wash
fractions. 89% and 90% of bound antibodies were eluted with
0.1 M glycine, 0.1 MNaCl pH 3 buffer from the OAg–ADH and
OAgoxADH columns respectively.
3.3. OAg–ADH column with human serum
Following the previous result confirming the functional
antigenic integrity of both forms of derivatised OAg bound to
NHS-Sepharose, we applied a protein preparation concentrated
from human serum containing polyclonal anti-Salmonella anti-
bodies to both columns. The proteins had beenprecipitated from
human serum using ammonium sulphate in order to reduce the
presence of contaminants that could interfere with the in-
teractions between OAg on the columns and corresponding
A B
C D
Fig. 2. Activated OAg from S. Typhimurium D23580 coupled to NHS-Sepharose can reversibly bind antibody. ELISA profile for the binding and elution of
anti-Salmonella Typhimurium O:4,5 IgG antibody from an OAg–ADH (A) and OAgoxADH NHS-Sepharose column (B). 300 μl of anti-Salmonella Typhimurium O:4,5
rabbit antiserum (Biorad), with an antibody concentration corresponding to 1666 ELISA units, was applied to the column (load). Flow through (FT) containing
unbound antibody was collected, and the column washed with 6 ml PBS (W1–3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4–6). Bound antibodies
were eluted with 5 ml 0.1 M glycine, 0.1 M NaCl pH 3 in 500 μl fractions (E1–10). 300 μl of ammonium sulphate-precipitated human serum proteins with an
anti-Salmonella Typhimurium antibody concentration corresponding to 1000 ELISA units was loaded on an OAg–ADH (C) and an OAgoxADH NHS-Sepharose
column (D) andwashing and elution performed as above. All fractions were collected and the concentration of anti-LPS IgG antibody in each fractionwas tested by
ELISA for antibody to LPS. Reciprocal of concentration of antibody giving an OD of 1 at λ 405 nm is plotted against column fraction collected.
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protein solution (with an antibody concentration corresponding
to 1000 ELISA units) were applied to each 1 ml column. A high
proportion (>75%) of the antibodies applied to the columns in
the serumprotein solution bound to the columnas shownby the
low signal in the ELISA for OAg antibodies in the flow through
and wash fractions (Fig. 2C and D). For the OAg–ADH column
(Fig. 2C), elution with 0.1 M glycine, 0.1 M NaCl pH 3 and
immediate neutralisation with 2 M Tris pH 9, resulted in a
recovery of only 14%of the bound antibodies. For theOAgoxADH
column, only 2% of the bound antibodies were eluted under the
same conditions (Fig. 2D). The same results were obtained
whether the ELISA was performed coating the plates with
purified OAg from S. Typhimurium D23580 or commercial LPS,
confirming that the antibodies detected were against the OAgand not the lipid A of LPS. Given that LPS is commercially
available, this was used to coat the plates for all subsequent
ELISA.
Only 50% of the antibodies bound to the resin when either
300 μl or 900 μl of whole serum (without performing serum
precipitation with ammonium sulphate) were applied to the
OAg–ADH column (data not shown). 900 μl corresponded to a
similar total amount of antibodies loaded after concentrating
the serum 2.5-fold with ammonium sulphate. When human
serum was precipitated using ammonium sulphate but not
concentrated during this step, and loaded on the OAg–ADH
column then, although the binding of antibody to the column
was high, the recovery of antibody using 0.1 M glycine, 0.1 M
NaCl pH 3.0 was only 5%. A 10-fold concentration of the
serum, instead of 2.5-fold, loading 300 μl with a concentration
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recovery of 15%, but was difficult to reproduce without high
loss of antibodies and was not used for further experiments.
Despite the apparent binding of the majority of human
anti-LPS antibody to both columns, the recovery of these
antibodies was very low, particularly with OAgoxADH. Eluted
fractions which lacked anti-LPS antibodies by ELISA also
lacked protein content according to absorption measure-
ments at 280 nm. This suggests that the poor recovery of
antibodies was not an artefact resulting from a lack of antibody
functionality due to the elution buffers used. Considering that
the binding capacity of OAg–ADH to NHS-Sepharose was not
lower than OAgoxADH, that only one step is required for its
synthesis, and that this derivatisation method can be generally
applied to OAg from different bacteria independent of its
structure, the OAg–ADH column was selected for performing
further experiments.
3.4. Elution under acidic conditions is optimal
With the aim of improving the recovery of antibody from
OAg–ADH columns, different elution buffers were tested.
Eight 1 ml OAg–ADH NHS columns were prepared, each with
an equal amount of OAg–ADH linked to the Sepharose
(3.5 mg/column), using the same batch of activated OAg.
Precipitated human serum proteins from the same donor as
in the previous experiments (with an antibody concentration
corresponding to 1300 ELISA units), were loaded onto each
column. The relative amount of unbound antibodies was very
low and comparable for all eight columns (Fig. 3A–B).
Glycine at acidic pH is commonly used as an elution buffer
(Narhi et al., 1997a, 1997b). We therefore tested 0.1 M glycine,
0.1 M NaCl at pH 3, pH 2.8, pH 2.6 and pH 2.4 (Fig. 3A) which
gave elutions containing 9%, 16%, 12% and 26% of the bound
antibodies respectively. We also examined the effect of using
20% ethanol, 4 MMgCl2 in 10 mMTris base pH 7, 8 M urea and
100 mM Tris base pH 9 (Fig. 3B) as elution buffers which
yielded 7%, 18%, 8% and1% of the bound antibodies respectively.
Polyclonal antibodies can be involved in different inter-
actions and have different affinities for the same antigen.
Consequently theymay require different conditions to disrupt
the antigen–antibody interaction. To determine if the recov-
ery of human polyclonal antibodies could be improved by
combining the two most efficient elution buffers tested, one
OAg–ADH column was loaded with precipitated human
serum proteins (antibody concentration corresponding to
1300 ELISA units) with sequential elution steps with 10 ml
0.1 M glycine, 0.1 M NaCl pH 2.4, and 10 ml 4 M MgCl2 in
10 mM Tris pH 7 and with washing with 6 ml PBS between
each step (Fig. 3C). Elution with 0.1 M glycine, 0.1 M NaCl
pH 2.4 recovered 28% of the bound antibody but no further
antibody was removed with MgCl2.
Glycine was also the optimal elution buffer when 300 μl
of commercial anti-O:4,5 antibodies (antibody concentration
corresponding to 1666 ELISA units) was loaded onto the
OAg–ADH column. Eluting with 4 M MgCl2 in 10 mM Tris
pH 7, only 44% of bound antibodies were removed (Fig. 3D).
Passing 3 ml 8 M urea and then 3 ml 20% ethanol through
the same column, no antibodies were removed whereas 3 ml
0.1 M glycine, 0.1 M NaCl pH 2.4 eluted a further 31% of
bound antibodies (Fig. 3D).3.5. Decreasing the amount of activated OAg coupled to
NHS-Sepharose increases the recovery of puriﬁed antibody
To investigate how the ratio of OAg coupled to NHS-
Sepharose in a column affects the recovery of purified anti-
bodies, 3.5 mg, 1 mg and 0.5 mg of OAg–ADH were immo-
bilised on 1 ml NHS-Sepharose columns. Equal amounts of
precipitated human serum proteins (antibody concentration
corresponding to 1200 ELISA units) were applied to each
column and 80% of loaded antibodies were retained by each
column, regardless of the amount of OAg linked to the matrix
(Fig. 4A–C).
Elution of antibodies bound to the column with 1 mg of
OAg–ADH linked, with 0.1 M glycine, 0.1 M NaCl pH 2.4
resulted in an increased recovery of purified antibodies
(Fig. 4B) of 51% compared to 26% for the original 3.5 mg
OAg–ADH column (Fig. 4A), while the yield decreased to 19%
for the columnwith the lowest amount of OAg–ADH (Fig. 4C).
Applying 1% SDS to the column at the end of the experiments
and analysing the SDS-eluate by SDS-PAGE revealed no protein
bands. This suggests that large amounts of antibody had not
been retained on the column following the various elutions.
4. Discussion
This study describes a new approach for the purification
of antibodies specific to S. Typhimurium OAg from human
serum by affinity chromatography.
We successfully coupled purified activated OAg from
invasive African S. Typhimurium D23580 to NHS-Sepharose.
As the key intermediate step to this process, two different
procedures were tested for introducing hydrazide groups
onto the OAg. In one case (OAg–ADH; Fig. 1B), the OAg chain
was linked via the KDO unit at the end of the core region,
proximal to the OAg, to a single ADH molecule. This method,
which is similar to the method proposed by Altman and
Bundle (Altman and Bundle, 1994), does not alter the avail-
able epitopes along the saccharide chain and can be applied
to OAg obtained from different bacteria regardless of their
structure. Reductive amination with ADH is a more rapid
process (1 h) than that required to link an amino group
(5 days) (Altman and Bundle, 1994), and was characterized by
a high OAg recovery and percentage of activation. The other
derivatised antigen, OAgoxADH (Fig. 1C), underwent prior
oxidation resulting in multiple ADH molecules linked to the
OAg chain that could potentially enhance the binding capacity
of the OAg to the NHS-Sepharose. This procedure modifies the
OAg chain structure with possible implications for antibody
binding and can only be applied to OAg containing diol groups
which are susceptible to oxidationwith sodiummetaperiodate.
Both OAg–ADH and OAgoxADH columns bound and gave a
similar recovery of commercial rabbit anti-Salmonella O:4,5
antibodies. However there was a greater recovery of purified
antibodies from the human serum for the OAg–ADH column
compared to the OAgoxADH column. Considering also that the
binding efficiency is not lower and OAg–ADH requires only one
step of synthesis, this method of activation was selected for
optimising the antibody extraction process.
One of the main caveats when selecting and producing an
affinity column is that modifications to the structure of the
target antigen can occur during activation or coupling of the
A B
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Fig. 3. Ability of different buffers to elute bound anti-OAg IgG antibodies from human or rabbit serum. Eight OAgADH-NHS-Sepharose columns were loaded with
300 μl of ammonium sulphate-precipitated human serum proteins with an anti-Salmonella Typhimurium antibody concentration corresponding to 1300 ELISA
units (load) and the flow through (FT) collected. Each column was washed with 6 ml PBS (W1–3), 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4–6). 5 ml of
different elution buffers were passed through each column: (A) 0.1 M glycine, 0.1 M NaCl pH 3 (squares), 0.1 M glycine, 0.1 M NaCl pH 2.8 (dotted line), 0.1 M
glycine, 0.1 M NaCl pH 2.6 (circles), 0.1 M glycine, 0.1 M NaCl pH 2.4 (solid line), (B) 100 mM Tris base pH 9 (squares), 20% ethanol, (dotted line), 4 M MgCl2 in
10 mM Tris base pH 7 (solid line), 8 M urea pH 7 (circles) and the eluates collected and neutralised if required (E1–10). (C) OAg–ADH column was loaded with
300 μl precipitated human serumwith an IgG antibody concentration corresponding to 1250 ELISA units, and bound antibodywas elutedwith 10 ml 0.1 M glycine,
0.1 M NaCl pH 3, followed by 10 ml 4 M MgCl2 in 10 mM Tris base pH 7 after washing with 6 ml PBS. (D) 300 μl of anti-Salmonella Typhimurium O:4,5 rabbit
antiserum (Biorad), with an antibody concentration corresponding to 1666 ELISA units, was applied to the OAg–ADH column (load), flow through (FT) containing
unbound antibody collected, and the column washed with 6 ml PBS (W1–3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4–6). Bound antibody was
sequentially eluted with 3 ml 4 MMgCl2 in 10 mM Tris base pH 7; then 3 ml 20% ethanol; 3 ml 8 M urea pH 7; and 3 ml 0.1 M glycine, 0.1 MNaCl pH 3with 6 ml
PBS passed through the column between buffers. Eluates were collected in 500 μl fractions (E1–10). Concentration of anti-OAg IgG antibody in each fraction was
tested by ELISA using LPS coated plates. Reciprocal of concentration of antibody giving an OD of 1 at λ 405 nm is plotted against column fraction collected.
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that antigen for its corresponding antibodies is frequently
reduced (Fox and Hechemy, 1978). Testing both OAg–ADH
and OAgoxADH columns with purified polyclonal antibodies
specific for O:4,5 of S. Typhimurium raised in rabbits, and
then with polyclonal antibodies from human serum, we
verified that both immobilised antigens were able to bind
antibodies (more than 90% of the applied antibodies boundfor the commercial anti-SalmonellaO:4,5 antiserum andmore
than 75% for human serum). This finding suggested that
the method used for OAg extraction and purification, and the
subsequent activation with ADH did not alter the antigenic
determinants present on the molecule.
When human serum proteins were applied to the columns,
the step of ammonium sulphate precipitation (Baines and
Thorpe, 1992; Page and Thorpe, 2002) was introduced before
AB
C
Fig. 4. Variation in amount of activated OAg immobilised to NHS-Sepharose
affects recovery of bound antibody from affinity columns. 300 μl ammonium
sulphate-treated human serum containing anti-Salmonella Typhimurium
antibodies corresponding to 1200 ELISA units was applied to three OAg–ADH
columns each with varying concentration of OAg–ADH linked to 1 ml
NHS-Sepharose: 3.5 mg/ml (A), 1 mg/ml (B), 0.5 mg/ml (C) and the flow
through (FT) was collected. Each columnwaswashed with 6 ml PBS (W1–3),
6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4–6) and bound antibody was
eluted with 5 ml 0.1 M glycine, 0.1 M NaCl pH 2.4 (E1–10). Concentration of
anti–OAg IgG antibody in each fraction was tested by ELISA using LPS coated
plates. Reciprocal of concentration of antibody giving an OD of 1 at λ 405 nm
is plotted against column fraction collected.
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the antibodies and remove a large number of contaminants such
as lipids and nucleic acids which could interfere with binding.Using purified polyclonal anti-Salmonella Typhimurium O:4,5
antibodies raised in rabbits, elution with 0.1 M glycine, 0.1 M
NaCl pH 3 was successful, allowing 89% of antibody recovery
(Fig. 2A and B).With human serum, only 14% of antibodieswere
eluted from the OAg–ADH column (Fig. 2C) and 2% from the
OAgoxADH column (Fig. 2D), using the same buffer. Differences
in the avidity of human and rabbit antibodies, particularly for
carbohydrate epitopes, may underlie the high recovery of
polyclonal rabbit antibodies and lower comparative recovery
of human antibodies with our columns.
Sera contain many polyclonal antibodies which recognize
and bind different epitopes on the same antigen with dif-
ferent binding affinities. Antigen–antibody binding involves
many weak interactions, including hydrogen bonds, van der
Waals forces, ionic and hydrophobic interactions (Smith-Gill
et al., 1982; Sakurabayashi, 1995; Mukkur, 1984; Smith-Gill,
1996). Therefore effective elution of polyclonal antibodies
may require several different elution conditions. Glycine at
acidic pH is commonly used to elute antibodies from antigen-
affinity column, but there are other possible solvents for this
purpose involving the use of alkaline pH, changes in ionic
strength, use of chaotropic salts (that disrupt the structure of
water and reduce hydrogen bonds and weaken hydrophobic
interactions), denaturants or organic buffers (Yarmush et al.,
1992; Jack, 1994). Testing glycine elution buffers at different
pH, pH 2.4 was the most effective (Fig. 3A), but recovery of
antibodies was still low (26%). Different buffers were then
tested: 20% ethanol to investigate the effect of an organic
solvent, 100 mM Tris pH 9 as alkaline buffer, 8 M urea as a
denaturant and 4 M MgCl2 to raise the ionic strength of the
solvent, with an accompanying weak chaotropic effect. The
highest recoverywith an alternative buffer was obtainedwith
4 M MgCl2 (18%; Fig. 3B). However, the yield was still lower
than that with 0.1 M glycine, 0.1 M NaCl pH 2.4 (26%; Fig. 3A),
and 4 M MgCl2 was not as effective as glycine at removing
commercial anti-Salmonella Typhimurium O:4,5 antibodies
either (Fig. 3D). To understand whether MgCl2 and glycine
were removing different sub-populations of human antibodies,
and in an attempt to increase the recovery, both buffers were
used sequentially, butMgCl2wasunable to elute any remaining
bound antibody (Fig. 3C).
It is possible that the majority of antibodies bound to the
column were successfully eluted, but that some did not fully
renature and therefore were no longer able to bind to LPS in
the ELISA. Even if the extracted antibodies refold in their
native conformation because of immediate neutralisation
and/or dialysis following elution (Narhi et al., 1997a, 1997b)
we did not investigate the effect of the elution buffers on
their conformation and so cannot exclude that an irreversible
denaturation occurred. Nevertheless, our 280 nm absorption
measurements of the column eluates indicated that those
fractions which lacked anti-LPS antibodies by ELISA also
lacked measurable protein content and thus were unlikely
to contain significant amounts of denatured antibody. We
verified that the ratio of antigen to antibody affected antibody
elution. Reduction in the amount of OAg–ADH coupled to
the resin from 3.5 mg to 1 mg per ml of resin, increased the
recovery of purified antibody from 26% to 51% working with
the same elution buffer (glycine pH 2.4). Decreasing the
concentration of linked OAg–ADH further to 0.5 mg per ml of
resin decreased the recovery to 19% (Fig. 4C). Differential
209C.M. O'Shaughnessy et al. / Journal of Immunological Methods 387 (2013) 199–210loading of the antigen on the resin could result in different
OAg chain conformations and a different exposure of the
epitopes and/or determine a different interaction with the
corresponding antibodies.
The present study describes the successful coupling of
OAg from S. Typhimurium to NHS-Sepharose in order to
produce an affinity matrix that is capable of purifying specific
antibodies from polyclonal human serum. The method can be
applied to OAg from different bacteria and it does not modify
OAg chain epitopes. Columns were filled with different OAg–
ADH preparations with consistent results and columns were
used at least 10 times with no deleterious effect on recovery
of antibodies. This process could potentially be adapted for
the purification of antibodies against other bacterial poly-
saccharides, as well as for the large scale purification of anti-
bodies against Salmonella OAg. As such, the method will be
useful for the investigation of the protective capacity of OAg
antibodies with different fine specificities in the context of
immunity to NTS, both in HIV-infected African adults and in
individuals immunised with OAg-based vaccines.
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